temozolomide + lonafarnib

Temozolomide + SCH66336 is an investigational combination therapy consisting of the alkylating agent temozolomide and the farnesyl transferase inhibitor lonafarnib (SCH66336). Temozolomide is a standard-of-care chemotherapy for glioblastoma that works by methylating DNA, primarily at the O6 position of guanine, leading to DNA damage and apoptosis. Lonafarnib is a small molecule inhibitor of farnesyl transferase, an enzyme responsible for the post-translational modification (farnesylation) of proteins such as Ras, which are involved in cell signaling and proliferation. The combination was evaluated in Phase II clinical trials for recurrent and progressive glioblastoma multiforme (GBM) under the hypothesis that inhibiting farnesylation could sensitize tumor cells to the cytotoxic effects of temozolomide or inhibit Ras-mediated survival pathways.

Brand names

TemodarSarasar

Other names

temozolomide + SCH66336